Key Highlights

  • Loss was USD 0.38 per share against an estimated USD 0.10 loss, and net loss was USD 4.7 million.
  • Total Revenue was USD 14.1 million, down 1%, while Recurring Revenue rose 17% to USD 12.6 million.
  • Procedure Volume rose 12% to 52,545, and the installed base reached about 450 systems worldwide.
  • Cash and investments were USD 12.6 million, and cash burn for the quarter was USD 900,000.

LENSAR (NASDAQ:LNSR), a maker of femtosecond laser systems for cataract surgery, reported a third quarter 2026 loss of USD 0.38 per share, wider than the USD 0.10 estimated loss. Net loss was USD 4.7 million, against USD 3.7 million a year earlier. Total revenue was USD 14.1 million, a 1% decrease from USD 14.3 million, which management attributed primarily to lower Capital system sales against a strong prior-year comparison.

For the nine months, revenue rose 4% to USD 44.1 million from USD 42.4 million, and the filing reports Net Income of USD 35.1 million, against a net loss of USD 32.8 million a year earlier.

Recurring Revenue, Margin and Installed Base

Gross margin was 58% for the quarter, against 42% a year ago, which management tied to an improved revenue mix and lower than historical service costs. Adjusted EBITDA was positive USD 1.7 million, against negative USD 300,000 a year earlier, though lower than USD 3.6 million in the second quarter because of seasonally lower revenue and a USD 1.1 million Tariff refund recorded then. A decline in selling, general and administrative expense reflected costs tied to the Alcon transaction in 2025, partly offset by about USD 1.2 million of strategic initiative spending. The company placed 10 ALLY systems in the quarter, bringing that installed base to about 225 from about 185 a year ago.

Recurring revenue increased 17% to USD 12.6 million and represented 89% of total revenue, against 75% a year ago. Procedure revenue grew 17% to USD 9.2 million as procedure volume rose 12% to 52,545 procedures. Service revenue rose USD 0.3 million, or 23%, and Lease revenue rose USD 0.2 million, or 10%. Product revenue decreased USD 0.7 million, or 6%.

United States sales were 77% of product and service revenue, up from 68% a year earlier. The installed base reached about 450 lasers worldwide, and the company exited September with 12 ALLY systems in Backlog awaiting installation.

Procedure Volume and Cash

Procedure volume was 54,094 in the first quarter, 58,682 in the second and 52,545 in the third of 2026, for 165,321 through nine months. The comparable nine-month figure for 2025 was 151,258 by the same quarterly series, so volume is running about 9% higher year to date. The fourth quarter of 2025 recorded 54,756 procedures.

Cash and investments totaled USD 12.6 million at September 30, against USD 18.0 million at December 31, 2025. Cash burn for the quarter was USD 900,000, which management described as an improvement over historical trends as cash Earnings improve.

Items to Follow

Conversion of the ALLY backlog into installations, procedure volume in the fourth quarter, the mix between recurring and system revenue and the cash balance are the figures to follow.